Two Sigma Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-765,550
| Closed | -$15.4M | – | 2867 |
|
|
2021
Q3 | $15.4M | Buy |
765,550
+421,200
| +122% | +$11.6M | 0.04% | 374 |
|
|
2021
Q2 | $12.9M | Sell |
344,350
-6,800
| -2% | -$208K | 0.03% | 475 |
|
|
2021
Q1 | $8.98M | Sell |
351,150
-180,900
| -34% | -$4.62M | 0.02% | 623 |
|
|
2020
Q4 | $11.7M | Sell |
532,050
-123,300
| -19% | -$2.72M | 0.03% | 516 |
|
|
2020
Q3 | $11.8M | Buy |
655,350
+32,800
| +5% | +$679K | 0.03% | 491 |
|
|
2020
Q2 | $15.8M | Buy |
622,550
+4,300
| +0.7% | +$92.6K | 0.05% | 391 |
|
|
2020
Q1 | $11.4M | Buy |
618,250
+177,700
| +40% | +$3.45M | 0.04% | 438 |
|
|
2019
Q4 | $9.71M | Buy |
440,550
+348,600
| +379% | +$7.01M | 0.02% | 607 |
|
|
2019
Q3 | $1.32M | Sell |
91,950
-27,600
| -23% | -$395K | ﹤0.01% | 1314 |
|
|
2019
Q2 | $1.88M | Sell |
119,550
-14,700
| -11% | -$200K | ﹤0.01% | 1238 |
|
|
2019
Q1 | $1.97M | Sell |
134,250
-31,300
| -19% | -$360K | 0.01% | 1236 |
|
|
2018
Q4 | $1.77M | Sell |
165,550
-21,400
| -11% | -$281K | ﹤0.01% | 1225 |
|
|
2018
Q3 | $2.85M | Buy |
186,950
+28,100
| +18% | +$409K | 0.01% | 1056 |
|
|
2018
Q2 | $1.95M | Buy |
158,850
+148,750
| +1,473% | +$1.87M | 0.01% | 1309 |
|
|
2018
Q1 | $97K | Buy |
+10,100
| New | +$109K | ﹤0.01% | 2229 |
|
Other funds holding DRNA
Two Sigma Advisers's DRNA Position: Q4 2021 in Review
Two Sigma Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 765,550 shares — an estimated $15.4M sold.
Two Sigma Advisers first reported a position in DRNA in Q1 2018 and held it in 15 quarters. The position peaked at $15.8M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Two Sigma Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Two Sigma Advisers sold 765,550 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $15.4M.
- Two Sigma Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 15 quarters.
- Two Sigma Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $15.8M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.